Evidence map›Paper›PMID 33062065›Full record

ArticleTherapeutic advances in medical oncology2020

Outcome of oncological patients admitted with COVID-19: experience of a hospital center in northern Italy.

Sara Cherri, Daniel H L Lemmers, Silvia Noventa, Mohammed Abu Hilal, Alberto Zaniboni

Open access · goldAbstract read
In one paragraph

Article in Therapeutic advances in medical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 3 pooled it
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 syntheses or guidelines pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 2 countries.

Sara CherriDepartment of Clinical Oncology, Fondazione Poliambulanza, Brescia, Italy.
Daniel H L LemmersDepartment of Surgery, Fondazione Poliambulanza, Brescia, Italy.ORCID https://orcid.org/0000-0002-3534-1089
Silvia NoventaDepartment of Oncology, Fondazione Poliambulanza, Brescia, Italy.
Mohammed Abu HilalDepartment of Surgery, Fondazione Poliambulanza, Brescia, Italy.
Alberto ZaniboniDepartment of Oncology, Fondazione Poliambulanza, Brescia, Italy.
Fondazione Poliambulanza Istituto Ospedaliero · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRecent literature regarding the outcome of cancer patients infected with COVID-19 are not encouraging. Nevertheless, current evidence on the risk and benefits of continuing oncological treatment of cancer patients during the pandemic remains insufficient. We provide our experience in a center with high access for patients with COVID-19-associated pneumonia in Lombardy, Italy. We conducted a retrospective study using a prospectively maintained database of patients admitted to our hospital between 25 February 2020 and 9 April 2020 with a confirmed diagnosis of COVID-19 pneumonia.

resultsA total of 53 patients with a history or current oncological disease were included in this study. Sixteen oncological patients (30.2%) died during hospitalization. Multivariable logistic regression analysis found that age (Odds ratio [OR]: 1.17,

conclusionThe presence of active oncological disease is independently related to mortality as well as age and diabetes. The majority of patients who died were frail. Careful evaluation of the risks and benefits of treatment in frail patients is needed, considering that difficult access to intensive care may have affected the mortality rate.

Indexed as

cancerchemotherapyCOVID-19immunodeficiencySARS-CoV-2

Identifiers

PMID33062065
PMCPMC7533930
OpenAlexW3091480835

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.